SCHEMBL4397609

SCHEMBL4397609

COc1ccc(Cn2c(-c3cccc(P(=O)(O)O)c3)c(-c3cccc(P(=O)(O)O)c3)n(Cc3ccc(OC)cc3)c2=O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 3/20 0.46
HDAC8 Q9BY41 2/20 0.46
HDAC6 Q9UBN7 2/20 0.46
HDAC11 Q96DB2 1/20 0.46
P2RX4 Q99571 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
MAPT P10636 7/20 0.43
ALDH1A1 P00352 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
THRB P10828 1/20 0.43
POLB P06746 1/20 0.43
GAA P10253 1/20 0.43
MAPK1 P28482 1/20 0.43
LMNA P02545 3/20 0.42
KDM4E B2RXH2 3/20 0.42
HTT P42858 2/20 0.42
CNR2 P34972 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
TSPO P30536 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4397339 0.80 P2RX4 (0.49) HDAC1HDAC8HDAC6HDAC11P2RX4
SCHEMBL4397603 0.73 MEN1 (0.44) HDAC6MEN1KMT2AMAPTALDH1A1
SCHEMBL13811863 0.73 MEN1 (0.44) HDAC6MEN1KMT2AMAPTALDH1A1
SCHEMBL7821285 0.68 CES2 (0.50) MEN1KMT2AALDH1A1SMN1; SMN2LMNA
SCHEMBL5891433 0.68 CASP3 (0.58) P2RX4MEN1KMT2AMAPTALDH1A1
SCHEMBL5875455 0.68 CASP3 (0.58) P2RX4MEN1KMT2AMAPTALDH1A1
SCHEMBL24071345 0.67 HDAC6 (0.65) HDAC1HDAC8HDAC6HDAC11MAPT
SCHEMBL11257792 0.66 MEN1 (0.64) HDAC1HDAC8HDAC6HDAC11P2RX4
SCHEMBL17242005 0.66 HDAC1 (0.60) HDAC1HDAC8HDAC6HDAC11P2RX4
SCHEMBL12353499 0.66 GRIK1 (0.62) HDAC8POLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7553809-B2 Fc receptor modulators and uses thereof ILEXUS PTY LIMITED (AU) 2009-06-30 US disclosed
US-20060057144-A1 Fc receptor modulators and uses thereof ILEXUS PTY LIMITED (AU) 2006-03-16 US disclosed
US-6835753-B2 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt ILEXUS PTY LIMITED (AU) 2004-12-28 US disclosed
US-20020061844-A1 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt ILEXUS PTY LIMITED 2002-05-23 US disclosed
US-6355683-B1 ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE ILEXUS PTY LIMITED (AU) 2002-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061844-A1 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt FCGR2A, FCGR1A, FCER2 HDAC1 3351/4885HDAC8 3208/4885HDAC6 2501/4885
US-20060057144-A1 Fc receptor modulators and uses thereof FCGR1A, FCER2, FCGR2A HDAC1 4004/4885HDAC8 3183/4885HDAC6 2433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.